drugset
drugset / Trial / NCT05633407

Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS

NCT05633407 ↗

Phase 2 Completed 53 enrolled argenx IQVIA Pty Ltd · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The study aims to investigate the safety, tolerability, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod compared to placebo in participants with post-COVID-19 postural orthostatic tachycardia syndrome (POTS) (post-COVID-19 POTS).

Timeline

Start
2022-09-23
Primary completion
2024-04-18
Completion
2024-04-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Efgartigimod Alfa Protein / enzyme biologic 10 mg/kg Intravenous

Indications

postural orthostatic tachycardia syndrome